Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Similar Posts
20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys
People are urged to avoid risky online buys and protect their health, as the MHRA seizes over 4.4 million doses of unlicensed erectile dysfunction medicines in 2025 alone.
Clinical trials for medicines: apply for approval in the UK
How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation
The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more quickly and boosting the UK’s competitiveness for global clinical research.
Class 4 Medicines Defect Notification: Levetiracetam Accord 100mg/ml oral solution, Accord Healthcare Limited, UK, EL(25)A/40
Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information.
MHRA welcomes Professor Jonathan Benger CBE as new CEO of NICE
Professor Benger’s leadership comes at a pivotal time as the MHRA and NICE deepen collaboration
MHRA approves inavolisib for the treatment of breast cancer
The MHRA has today, 26 November 2025, approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR-positive